Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss
Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight ...
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Devdiscourse5d
Novo Nordisk's CagriSema: A Weight-Loss Hopeful Under Market Scrutiny
Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...
Devdiscourse5d
Novo Nordisk's CagriSema: A Breakthrough in Weight Loss for Type 2 Diabetes
Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...